BNP Paribas Financial Markets Increases Stock Holdings in BioNTech SE Sponsored ADR $BNTX

by · The Cerbat Gem

BNP Paribas Financial Markets lifted its stake in BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report) by 43.0% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,578,094 shares of the company’s stock after purchasing an additional 474,796 shares during the quarter. BNP Paribas Financial Markets’ holdings in BioNTech were worth $150,235,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Forsta AP Fonden purchased a new position in BioNTech during the 4th quarter valued at $798,000. SBI Okasan Asset Management Co.Ltd. purchased a new position in BioNTech during the 4th quarter valued at $352,000. Geode Capital Management LLC boosted its holdings in BioNTech by 4.0% during the 4th quarter. Geode Capital Management LLC now owns 120,605 shares of the company’s stock valued at $11,482,000 after acquiring an additional 4,615 shares during the period. Legal & General Group Plc boosted its holdings in BioNTech by 3.1% during the 4th quarter. Legal & General Group Plc now owns 321,111 shares of the company’s stock valued at $30,636,000 after acquiring an additional 9,528 shares during the period. Finally, Leonteq Securities AG purchased a new position in BioNTech during the 4th quarter valued at $2,609,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Up 2.7%

BNTX opened at $95.95 on Friday. The firm has a market cap of $24.26 billion, a price-to-earnings ratio of -16.32 and a beta of 1.36. The company has a current ratio of 8.80, a quick ratio of 8.74 and a debt-to-equity ratio of 0.01. BioNTech SE Sponsored ADR has a 12 month low of $79.52 and a 12 month high of $124.00. The stock has a fifty day moving average price of $94.46 and a 200-day moving average price of $99.49.

BioNTech (NASDAQ:BNTX – Get Free Report) last released its quarterly earnings results on Saturday, February 14th. The company reported ($0.39) EPS for the quarter. The company had revenue of $1.06 billion during the quarter. BioNTech had a negative return on equity of 5.30% and a negative net margin of 44.39%. As a group, equities research analysts anticipate that BioNTech SE Sponsored ADR will post -4.71 earnings per share for the current fiscal year.

BioNTech declared that its Board of Directors has authorized a stock buyback program on Thursday, May 7th that allows the company to buyback $1.00 billion in outstanding shares. This buyback authorization allows the company to purchase up to 4.2% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on BNTX shares. TD Cowen decreased their target price on BioNTech from $116.00 to $94.00 and set a “hold” rating for the company in a research report on Wednesday, March 11th. Truist Financial raised BioNTech to a “strong-buy” rating in a research report on Wednesday, March 25th. UBS Group raised BioNTech from a “neutral” rating to a “buy” rating and lifted their target price for the company from $117.00 to $135.00 in a research report on Wednesday. BMO Capital Markets decreased their target price on BioNTech from $143.00 to $128.00 and set an “outperform” rating for the company in a research report on Wednesday, March 11th. Finally, Sanford C. Bernstein started coverage on BioNTech in a research report on Thursday, May 21st. They set a “market perform” rating and a $96.00 target price for the company. One investment analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $129.56.

Get Our Latest Analysis on BNTX

Insiders Place Their Bets

In related news, COO Sierk Poetting sold 50,000 shares of the business’s stock in a transaction on Wednesday, April 22nd. The stock was sold at an average price of $110.56, for a total transaction of $5,528,000.00. Following the transaction, the chief operating officer directly owned 399,387 shares in the company, valued at $44,156,226.72. The trade was a 11.13% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 19.20% of the stock is currently owned by company insiders.

About BioNTech

(Free Report)

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.

Read More

Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE Sponsored ADR (NASDAQ:BNTX – Free Report).